Chautauqua Nursing and Rehabilitation Center to offer Monoclonal Antibodies for treatment of High Risk Covid-19 Patients


DUNKIRK, NY – VestraCare, an operator of high-quality nursing and rehabilitation facilities, is pleased to announce that its Chautauqua Nursing and Rehabilitation Center, CNRC, is now offering monoclonal antibody infusions for the treatment of high-risk Covid-19 patients.


In November 2020, the FDA (Food and Drug Administration) issued EUA (emergency use authorization) for the use of monoclonal antibodies for the treatment of high-risk patients with mild to moderate Covid-19 symptoms at risk for progression to severe illness and hospitalization. This is the same treatment that was given to the US President.


CNRC has the advanced clinical setting necessary to administer the infusions, as well as a highly skilled nursing staff and on-site medical providers. “The monoclonal antibody infusions have proven to be an effective method of treatment for those who qualify, with many patients showing positive and timely responses,” stated Administrator Colleen Hart, LNHA.


The clinical team at CNRC has been working closely with its Medical Director, Kent Lieber, MD, to implement protocols for administration and aftercare in concert with those specified in the EUA.


The antibodies are made with proteins created in a laboratory and are designed to mimic the antibodies created in the body’s immune system to ward off the virus and fight infection. CNRC will receive the compounded medication from PharmScripts on a per-patient basis.


Residents will receive the treatment in-house in the comfort of a familiar environment. The team at CNRC provides continuous monitoring in a designated area prior, during and post-infusion.


Chautauqua Nursing and Rehabilitation Center provides 24-hour skilled nursing care, subacute rehabilitation and short-term respite care. For more information, visit


No responses yet

Leave a Reply

Follow Blog via Email

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 1 other subscriber